Andrew Bristol
Geen lopende functies
Profiel
Dr. Andrew Bristol is Vice President-Research & Development at Synthetic Biologics, Inc.
Dr. Bristol was previously employed as Senior Vice President-Research & Development by Neogenix Oncology, Inc., Deputy Director-Immunology by Genetic Therapy, Inc., and a Research Associate by Genetics Institute LLC.
He received his undergraduate degree from the University of California, Berkeley and a doctorate degree from Tufts University.
Eerdere bekende functies van Andrew Bristol
| Bedrijven | Functie | Einde |
|---|---|---|
| THERIVA BIOLOGICS, INC. | Hoofd Techniek/Wetenschap/O&O | - |
Genetic Therapy, Inc.
 Genetic Therapy, Inc. Miscellaneous Commercial ServicesCommercial Services Genetic Therapy, Inc. develops human gene therapy products for the treatment of genetic and acquired diseases. The company also conducts research on human gene development. Genetic Therapy was founded by M. James Barrett in May 1986 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | - |
Genetics Institute LLC
 Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Neogenix Oncology, Inc.
 Neogenix Oncology, Inc. Medical SpecialtiesHealth Technology Founded in December 2003, Neogenix Oncology is a clinical stage biotechnology company focused on developing therapeutic and diagnostic products for the early detection and treatment of cancer. The company's antibody drug candidates and diagnostics are designed to detect and target the tumor without destroying healthy cells. Neogenix Oncology is uniquely positioned to create innovative therapeutics through the use of proprietary cancer vaccines, several of which have demonstrated success in human trials. By marrying this platform with today's breakthrough technologies, the company is developing antibody therapeutics that could change the way it detects and treats cancer. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Andrew Bristol
| Tufts University | Doctorate Degree |
| University of California, Berkeley | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| THERIVA BIOLOGICS, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Neogenix Oncology, Inc.
Neogenix Oncology, Inc. Medical SpecialtiesHealth Technology Founded in December 2003, Neogenix Oncology is a clinical stage biotechnology company focused on developing therapeutic and diagnostic products for the early detection and treatment of cancer. The company's antibody drug candidates and diagnostics are designed to detect and target the tumor without destroying healthy cells. Neogenix Oncology is uniquely positioned to create innovative therapeutics through the use of proprietary cancer vaccines, several of which have demonstrated success in human trials. By marrying this platform with today's breakthrough technologies, the company is developing antibody therapeutics that could change the way it detects and treats cancer. | Health Technology |
Genetic Therapy, Inc.
Genetic Therapy, Inc. Miscellaneous Commercial ServicesCommercial Services Genetic Therapy, Inc. develops human gene therapy products for the treatment of genetic and acquired diseases. The company also conducts research on human gene development. Genetic Therapy was founded by M. James Barrett in May 1986 and is headquartered in Gaithersburg, MD. | Commercial Services |
Genetics Institute LLC
Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Health Technology |
